KR20220125232A - Ahr 억제제 및 이의 용도 - Google Patents
Ahr 억제제 및 이의 용도 Download PDFInfo
- Publication number
- KR20220125232A KR20220125232A KR1020227021773A KR20227021773A KR20220125232A KR 20220125232 A KR20220125232 A KR 20220125232A KR 1020227021773 A KR1020227021773 A KR 1020227021773A KR 20227021773 A KR20227021773 A KR 20227021773A KR 20220125232 A KR20220125232 A KR 20220125232A
- Authority
- KR
- South Korea
- Prior art keywords
- cancer
- compound
- patient
- pharmaceutically acceptable
- sdi
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962940514P | 2019-11-26 | 2019-11-26 | |
US62/940,514 | 2019-11-26 | ||
US202063106530P | 2020-10-28 | 2020-10-28 | |
US63/106,530 | 2020-10-28 | ||
PCT/US2020/062116 WO2021108469A1 (en) | 2019-11-26 | 2020-11-25 | Ahr inhibitors and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20220125232A true KR20220125232A (ko) | 2022-09-14 |
Family
ID=73856333
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020227021773A KR20220125232A (ko) | 2019-11-26 | 2020-11-25 | Ahr 억제제 및 이의 용도 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230026232A1 (zh) |
EP (1) | EP4065090A1 (zh) |
JP (1) | JP2023503167A (zh) |
KR (1) | KR20220125232A (zh) |
CN (1) | CN115279347A (zh) |
AU (1) | AU2020391451A1 (zh) |
BR (1) | BR112022010143A2 (zh) |
CA (1) | CA3159315A1 (zh) |
IL (1) | IL293325A (zh) |
MX (1) | MX2022006312A (zh) |
WO (1) | WO2021108469A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4065582A1 (en) | 2019-11-26 | 2022-10-05 | Ikena Oncology, Inc. | Polymorphic carbazole derivatives and uses thereof |
WO2024059142A1 (en) * | 2022-09-14 | 2024-03-21 | Arcus Biosciences, Inc. | Dispersions of etrumadenant |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201103837D0 (en) * | 2011-03-07 | 2011-04-20 | Oxagen Ltd | Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid |
MX2019012431A (es) | 2017-04-21 | 2020-08-03 | Ikena Oncology Inc | Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. |
-
2020
- 2020-11-25 WO PCT/US2020/062116 patent/WO2021108469A1/en unknown
- 2020-11-25 US US17/779,893 patent/US20230026232A1/en active Pending
- 2020-11-25 CA CA3159315A patent/CA3159315A1/en active Pending
- 2020-11-25 AU AU2020391451A patent/AU2020391451A1/en active Pending
- 2020-11-25 MX MX2022006312A patent/MX2022006312A/es unknown
- 2020-11-25 IL IL293325A patent/IL293325A/en unknown
- 2020-11-25 BR BR112022010143A patent/BR112022010143A2/pt unknown
- 2020-11-25 CN CN202080092187.6A patent/CN115279347A/zh not_active Withdrawn
- 2020-11-25 JP JP2022530740A patent/JP2023503167A/ja not_active Withdrawn
- 2020-11-25 EP EP20828448.9A patent/EP4065090A1/en active Pending
- 2020-11-25 KR KR1020227021773A patent/KR20220125232A/ko unknown
Also Published As
Publication number | Publication date |
---|---|
AU2020391451A1 (en) | 2022-06-16 |
BR112022010143A2 (pt) | 2022-08-09 |
EP4065090A1 (en) | 2022-10-05 |
WO2021108469A1 (en) | 2021-06-03 |
JP2023503167A (ja) | 2023-01-26 |
CA3159315A1 (en) | 2021-06-03 |
IL293325A (en) | 2022-07-01 |
CN115279347A (zh) | 2022-11-01 |
US20230026232A1 (en) | 2023-01-26 |
MX2022006312A (es) | 2022-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6892448B2 (ja) | 悪性腫瘍の処置の方法 | |
KR102606253B1 (ko) | 2-(tert-부틸아미노)-4-((1r,3r,4r)-3-하이드록시-4-메틸사이클로헥실아미노)-피리미딘-5-카복사마이드의 제형 | |
CN109069410A (zh) | 用于治疗血液恶性肿瘤和实体瘤的idh1抑制剂 | |
JP5547066B2 (ja) | 治療用組成物およびその使用 | |
JP2010540459A (ja) | Cox‐2阻害薬及びegfr[erbb1]とher‐2[erbb2]の二重阻害薬を用いた癌を治療するための併用療法 | |
JP2018509458A (ja) | ブルトン型チロシンキナーゼ阻害剤の共結晶 | |
JP2018509457A (ja) | ブルトン型チロシンキナーゼ阻害剤の溶媒和形態 | |
JP2020533283A (ja) | エンドキシフェンを製造および使用する方法 | |
KR20220125232A (ko) | Ahr 억제제 및 이의 용도 | |
JP2010540460A (ja) | COX‐2阻害薬と抗HER2[ErbB2]抗体の混合物又はCOX‐2阻害薬とHER2[ErbB2]受容体チロシンキナーゼ阻害薬の混合物を用いた癌の治療 | |
KR20140129164A (ko) | 히스톤 데아세틸라아제 억제제 및 파조파닙의 조합물 및 이의 용도 | |
TW201302732A (zh) | 光學活性吡唑基胺基喹唑啉及其醫藥組合物及使用方法 | |
JP2022524424A (ja) | 向上したバイオアベイラビリティを有する化合物形態及びその製剤 | |
CN115279345A (zh) | 8-氯-n-(4-(三氟甲氧基)苯基)喹啉-2-胺的无定形固体分散体 | |
US20210353648A1 (en) | Grapiprant unit dosage forms | |
KR20130078147A (ko) | 일정한 입도를 갖는 4,5―디아릴―3(2h)―퓨라논 유도체를 포함하는 약학 조성물 | |
JP2023524808A (ja) | アビラテロン酢酸エステル及びニラパリブの組み合わせでの前立腺癌の治療 | |
US10980765B2 (en) | Isothiocyanatostilbenes as a novel method and product for treating cancer | |
KR102257685B1 (ko) | Cox-2 억제제를 유효성분으로 포함하는 소염진통 예방 또는 치료용 정제 조성물 | |
TW202245780A (zh) | 用於治療神經膠質母細胞瘤之方法 |